INJECTABLES/MEDICATIONS ADMINISTERED UNDER THE MEDICAL BENEFIT Authorization Required List Not Related to Bleeding and Clotting Disorders

Size: px
Start display at page:

Download "INJECTABLES/MEDICATIONS ADMINISTERED UNDER THE MEDICAL BENEFIT Authorization Required List Not Related to Bleeding and Clotting Disorders"

Transcription

1 INJECTABLES/MEDICATIONS ADMINISTERED UNDER THE MEDICAL BENEFIT Authorization Required List Not Related to Bleeding and Clotting Disorders CareOregon and Revised 6/01/2016 INSTRUCTIONS FOR USE: 1. This list contains Injectable Medications covered under the Medical Benefit that REQUIRE AUTHORIZATION. Always search by J-Code AND by Drug Name because J-Codes change. Note: See and OHP columns for pertinent information. Prior Authorization Request forms can be found at 2. This document should NOT be used for: hemophilia/factor/bleeding products OR drugs furnished by a pharmacy (For Medicaid, CareOregon requires buy and bill for drugs administered in office in accordance with OAR: (3)). 3. VACCINES: Only certain vaccines with unique benefits are listed below. Vaccines not listed are still subject to appropriate use/billing practices including Medicare billing requirements (see following). For COA members: Most preventative vaccines are covered by Part D (pharmacy benefit) and not by Part B (office buy and bill). Typically, Part B only covers pneumococcal, influenza, hepatitis B for individuals at high or intermediate risk, and tetanus toxoid or rabies directly related to the treatment of an injury or direct exposure. All other vaccines should be dispensed at a pharmacy for Medicare members. 4. If the drug is NOT found on this list AND will be Buy and Bill (Supplied and billed under the Medical Benefit by the Provider) then it does NOT require authorization. EXCEPTION: New drugs to the market not found on this list. Dump Codes C9399, J3590 and J9999 require Prior Authorization for ANY medication being billed under them whether listed below or not. 5. J3490 (unclassified drugs)- Should only be used for drugs without a more specific code. Auth only required IF drug name is on the list below. **Always use the most active code based on date of service and CMS HCPCS codes** J0129 Abatacept Orencia SQ- Med D only IV-PA Required J0586 Abobotulinumtoxin A Dysport J0135 Adalimumab Humira - Part D only

2 J9354 Ado-trastuzumab Kadcyla J0178 Aflibercept Eylea J0180 Agalsidase beta Fabrazyme J3490 Albiglutide Tanzeum - Part D only - Pharmacy Benefit J0215 Alefacept Amevive J0202 Q9979* Alemtuzumab Lemtrada J0202 Alemtuzumab Campath J9010* J0205 Alglucerase Ceredase J0221 Alglucosidase alfa Lumizyme J0220 Alglucosidase alfa Myozyme J3490 Alirocumab Praluent - Part D only - Pharmacy Benefit J0256 Alpha-1 Proteinase Inhibitor Prolastin J0257 Alpha-1 Proteinase Inhibitor (human) Glassia J0270 Alprostadil, injection Caverject, Edex Not covered Not covered J0275 Alprostadil, urethral suppository Muse Not covered Not covered J3450 Anakinra Kineret - Part D only J0365 Aprotinin Trasylol J9019 Asparaginase Erwinia Erwinaze J0401 Aripiprazole, injection extended release Abilify Maintena - Excluded Bill to C9470 J3490 Aripiprazole, injection extended release Aristada - Excluded Bill to J3490, J3590 Asfotase alfa Strensiq - Part D only - Pharmacy Benefit J7330 Autologous Cultured Chondrocytes Carticel Not covered Not covered J0485 Belatacept Nulojix J0490 Belimumab Benlysta

3 J9032 C9442*, J9999* Belinostat Beleodaq J9033 Bendamustine Treanda J9999 or J9033 Bendamustine Bendeka J9035 Bevacizumab for CHEMOTHERAPY * bevacizumab for eye use should use J7999 and no authorization is required Avastin for CHEMOTHERAPY J9039 Blinatumomab Blincyto C9449* J9041 Bortezomib Velcade J9042 Brentuximab vedotin Adcetris J0571 Buprenorphine Subutex Part D only Pharmacy J0572 Buprenorphine/Naloxone Suboxone Dispenses= J0573 Buprenorphine/Naloxone Suboxone Pharmacy Pharmacy Benefit J0574 Buprenorphine/Naloxone Suboxone Dispenses: Phamacy with PA J0575 Buprenorphine/Naloxone Suboxone Benefit with PA. Clinic Dispenses: Excluded Clinic Dispenses= Behavioral Health Benefit with PA J0598 C1 esterase inhibitor Cinryze J9043 Cabazitaxel Jevtana J0630 Calcitonin salmon Miacalcin, Calcimar - Part D only No PA Reqd J0638 Canakinumab Ilaris J7340 Carbidopa/Levodopa Duopa J9047 Carfilzomib Kyprolis J7335 Capsaicin patch Qutenza J0712 Ceftaroline fosamil Teflaro J0714 J3490* Ceftazidime/Avivactam Avycaz

4 J0717 Certolizumab Cimzia - Part D only J9055 Cetuximab Erbitux J0775 Collagenase clostridium histolyticum Xiaflex J0800 Corticotropin Acthar gel - Part D only J9999 Daratumumab Darzalex J0881 Darbepoetin Aranesp J0894 Decitabine Dacogen J0897 Denosumab Prolia, Xgeva J2597 Desmopressin acetate DDAVP J9999 Dinutuximab Unituxin J9171 Docetaxel Taxotere Q2049 Doxorubicin, liposomal. Imported Lipodox Q2050 Doxorubicin, liposomal Doxil J1300 Eculizumab Soliris J1322 Elosulfase alfa Vimizim J9999 Elotuzumab Empliciti J1324 Enfuvirtide Fuzeon Part D only, No auth required. J0885 Epoetin alfa (non-esrd) Procrit J0888 Epoetin beta (non-esrd) NeoRecormon J1325 Epoprostenol Flolan S0155 Epoprostenol Diluent Flolan Diluent J9179 Eribulin Halaven J1438 Etanercept Enbrel - Part D only J7527 Everolimus (oral) Afinitor, Zortress J3490 Exenatide Byetta, Bydureon - Part D only - Pharmacy Benefit J1439 Ferric carboxymaltose Injectafer J7311 Fluocinolone implant Retisert J7313 C9450* Fluocinolone implant Iluvien

5 J2680 Fluphenazine No PA Reqd - Excluded Bill to J9395 Fulvestrant Faslodex J1458 Galsulfase Naglazyme J1595 Glatiramer Acetate Copaxone - Part D only Pharmacy Benefit C9293 Glucarpidase Voraxaze J3590 Golimumab Simponi - SQ- Med D only J1602 Golimumab, IV Simponi Aria J9202 Goserelin Zoladex J2940 Growth Hormone (somatrem) Various - Part D only J2941 Growth Hormone (somatropin) Various - Part D only J1630 Haloperidol Haldol No PA Reqd - Excluded Bill to J1631 Haloperidol Haldol No PA Reqd - Excluded Bill to J1675 Histrelin Supprelin - Part D only J9226 Histrelin implant Supprelin LA J9225 Histrelin implant Vantas or Human Papilloma Virus (HPV) vaccine Gardasil, Cervarix - Part D only No auth req. for ages <19 VFC J7323 Hyaluronan or Derivative Euflexxa Not covered J7326 Hyaluronan or Derivative Gel-One Not covered J7321 Hyaluronan or Derivative Hyalgan or Supartz Not covered J7324 Hyaluronan or Derivative Orthovisc Not covered J7325 Hyaluronan or Derivative Synvisc, Synvisc-One Not covered J7327 Hyaluronan or Derivative Monovisc Not covered J7328 Hyaluronan or Derivative Gel-Syn Not covered Q9980 Hyaluronan or Derivative GenVisc Not covered C9471 Hyaluronan or Derivative Hymovis Not covered J1725 Hydroxyprogesterone caproate Makena J1741 Ibuprofen (IV) Caldolor, NeoProfen

6 J1744 Icatibant Firazyr - Part D only No PA Reqd Q4074 Iloprost, Inhaled Ventavis J1786 Imiglucerase Cerezyme J1566 Immune Globulin lyophilized, IV Carimune J1460 Immune Globulin, IM GamaStan SD J1560 J1572 Immune Globulin, IV Flebogamma J1569 Immune Globulin, IV Gammagard J1557 Immune Globulin, IV Gammaplex J1561 Immune Globulin, IV Gamunex J1559 Immune Globulin, SQ Hizentra - Part D only J1599 Immune Globulin, IV Nonlyophilized (NOS) J1568 Immune Globulin, IV Octagam J1459 Immune Globulin, IV, Privigen J1556 Immune Globulin, IV Bivigam J1575 Immune Globulin/hyaluronidase Hyqvia J0588 Incobotulinumtoxin A Xeomin J1745 Infliximab Remicade Influenza Virus Vaccine, High Dose Fluzone High Dose - Part D only No auth req. for age 65 and older J1815 Insulin Humalog, Lantus, etc - Part D only No PA Reqd J1817 Insulin for administration through pump Humalog, Novolog, etc - Part D only No PA Reqd J9215 Interferon Alfa N-3 Alferon-N J9213 Interferon Alfa-2a Roferon A - Part D only J9214 Interferon Alfa-2b Intron A, Rebetron Kit J9212 Interferon Alfacon-1 Infergen - Part D only Q3028 Inferferon Beta-1a, SQ use Rebif, Rebidose - Part D only Pharmacy Benefit Q3027 Inferferon Beta-1a, IM use Avonex - Part D only Pharmacy Benefit J1830 Interferon Beta-1b Betaseron - Part D only Pharmacy Benefit J9216 Interferon Gamma-1B Actimmune - Part D only J7300 Intrauterine Copper Contraceptive Not Covered± No PA Reqd J9228 Ipilimumab Yervoy

7 C9474 J9999 J1833 C9456*, J3490* Irinotecan liposome Onivyde Isavuconazonium Cresemba (IV) J9207 Ixabepilone Ixempra J1931 Laronidase Aldurazyme J9218 Leuprolide Lupron - Part D only J9217 Leuprolide depot Lupron Depot, Eligard J1950 Leuprolide depot suspension Lupron Depot, J9219 Leuprolide implant Lupron Implant J0641 Levoleucovorin Fusilev J7301 Levonorgestrel IUD Skyla Not Covered± No PA Reqd J7297 Levonorgestrel IUD 52 mg, 3 year Liletta Not Covered± No PA Reqd J7302* J7298 Levonorgestrel IUD 52 mg, 5 year Mirena Not Covered± No PA Reqd J7302* J3490 Liraglutide Victoza - Part D only J2010 Lincomycin Lincocin Not Covered J2020 Linezolid Zyvox C9497 Loxapine, inhaled powder Adasuve No PA Reqd - Excluded Bill to J3490 Metreleptin Myalept J2170 Mecasermin Increlex, Iplex - Part D only J9245 Melphalan Alkeran J3590 Melphalan Evomela C9473 Mepolizumab Nucala J3590 J7309 Methyl Aminolevulinate Levulan, Kerastick, Metvixia J2212 Methylnaltrexone Relistor - Part D only J3490 Mipomersen Kynamro - Part D only S1090 Mometasone Furoate Sinus Implant Propel J2315 Naltrexone Extended-release injection Vivitrol

8 J2323 Natalizumab Tysabri C9475 Necitumumab Portrazza J9999 J9261 Nelarabine Arranon J8655 Q9978* Netupitant-palonesetron oral Akynzeo J9299 Nivolumab Opdivo C9453*, J9999* J9301 Obinutuzumab Gazyva J7316 Ocriplasmin Jetrea J2354 Octreotide Sandostatin - Part D only No PA Reqd J9302 Ofatumumab Arzerra J2358 Olanzapine Zyprexa Relprevv No PA Reqd - Excluded Bill to J9262 Omacetaxine mepesuccinate Synribo J2357 Omalizumab Xolair J0585 Onabutolinumtoxin-A Botox J9263 Oxaliplatin Eloxatin J9264 Paclitaxel protein-bound Abraxane J2426 Paliperidone Invega Sustenna - Excluded Bill to Palivizumab Synagis 1. For OHSU providers only, submit request to CareOregon and use own supply. 2. For all other providers, submit request to CareOregon and obtain Synagis from our preferred provider. See the request form for details on the preferred provider. J9303 Panitumumab Vectibix J2440 Papaverine N/A - Part D only No PA Reqd J3490 Parathyroid hormone Natpara - Part D only

9 J2502 Pasireotide Signifor LAR C9454*, J3490* J2504 Pegademase bovine Adagen J2503 Pegaptanib Macugen J9266 Pegaspargase Oncaspar J0890 Peginesatide Omontys J2507 Pegloticase Krystexxa J3590 Pegvisomant Somavert - Part D only J3590, S0145 Pegylated Interferon alfa-2a Pegasys - Part D only J3590, S0148 Pegylated Interferon alfa-2b Peg-Intron - Part D only J3490 Pegylated Interferon alfa-2b Sylatron - Part D only J9271 C9027*, J3590*, Pembrolizumab Keytruda J9999* J9305 Pemetrexed Alimta J9306 Pertuzumab Perjeta J2760 Phentolamine Regitine - Part D only No PA Reqd J2562 Plerixafor Mozobil J9307 Pralatrexate Folotyn J3490 Pramlintide Symlin - Part D only J3490 Polidocanol Varithena J9308 Ramucirumab Cyramza C9025*, J3590*, J9999* J2778 Ranibizumab Lucentis J2793 Rilonacept Arcalyst J0587 RimabotulinumtoxinB Myobloc J2794 Risperidone Risperdal Consta No PA Reqd - Excluded Bill to J9310 Rituximab Rituxan Q0181 Rolapitant Varubi J9315 Romidepsin Istodax J2796 Romiplostim Nplate

10 J3490, J3590 Sebelipase alfa Kanuma J3590 Secukinumab Cosentyx - Part D only J2860 C9455*, J9999*, Siltuximab Sylvant J3590* Q2043 Sipuleucel-T Provenge J3030 Sumatriptan succinate Imitrex Injection - Part D only No PA Reqd J3060 Taliglucerase alfa Elelyso J9999 Talimogene laherparepvec Imlygic C9472 J9328 Temozolomide Temodar J9330 Temsirolimus Torisel J3110 Teriparatide Forteo - Part D only J1071 Testosterone cypionate Various No PA Reqd J3121 Testosterone enanthate Various No PA Reqd J3145 Testosterone undecanoate Aveed J3243 Tigecyclcine Tygacil J3262 Tocilzumab Actemra J9999 Trabectedin Yondelis J9355 Trastuzumab Herceptin J3285 Treprostinil Remodulin J7686 Treprostinil Tyvaso J3315 Triptorelin Trelstar J3355 Urofollitropin Metrodin, Bravelle, Fertinex - Part D only Not covered J3357 Ustekinumab Stelara Varicella zoster immune globulin Varizig J3380 Vedolizumab Entyvio C9026* J3385 Velaglucernase alfa Vpriv J9371 Vincristine sulfate liposome Marqibo J3486 Ziprasidone Geodon No PA Reqd - Excluded Bill to J9400 Ziv-aflibercept Zaltrap

11 90736 Zoster Vaccine live Zostavax - Part D only Age<60 req PA C9399 Unclassified Drug or biologic J3590 Unclassified Biologics J9999 Not otherwise classified, Anti-neoplastic Drugs * Note that ALL codes are subject to change according to CMS HCPCS Codes quarterly updates. CareOregon requires the active code from the date of service to be provided. When in doubt, please always refer to the generic name listing when checking if PA is required. ± Coverage excluded by Medicare. For member's with dual eligibilty, coverage may be offered under their secondary Medicaid (OHP). Drug's with REMOVED PA requirements as of 4/1/16 J9045 Carboplatin Paraplatin No No J9201 Gemcitabine Gemzar No No J9206 Irinotecan Camptosar No No J9267 Paclitaxel Taxol No No J9265* J9185 Fludarabine Fludara No No

Fourth Quarter 2014 Provider Connection

Fourth Quarter 2014 Provider Connection Healthy Michigan Plan Health Risk Assessments Do you need clarification or information related to the completion of the Healthy Michigan Plan (HMP) member Health Risk Assessment (HRA) form? Resources and

More information

Local Coverage Article: Self-Administered Drug Exclusion List (A51866)

Local Coverage Article: Self-Administered Drug Exclusion List (A51866) Local Coverage Article: Self-Administered Drug Exclusion List (A51866) Contractor Information Contractor Name Novitas Solutions, Inc. Article Information General Information Article ID A51866 General Article

More information

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12 STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What

More information

REFERRAL/AUTHORIZATION GUIDELINES Commercial Plans

REFERRAL/AUTHORIZATION GUIDELINES Commercial Plans Moda Health Referral/Authorization Guidelines Oregon updated September 2014 Page 1 of 7 REFERRAL/AUTHORIZATION GUIDELINES Commercial Plans Referral & Authorization Information Referral and authorization

More information

Medical Prior Authorization List For prescription drug requirements, see plan formularies.

Medical Prior Authorization List For prescription drug requirements, see plan formularies. For prescription drug requirements, see plan formularies. General Information These requirements are administered by Health First Health Plans ( Health Plans ). Benefits are determined by the plan. Items

More information

2016 MDwise HIP Medical Services that Require Prior Authorization

2016 MDwise HIP Medical Services that Require Prior Authorization 2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport

More information

2016 MDwise HIP Medical Services that Require Prior Authorization

2016 MDwise HIP Medical Services that Require Prior Authorization 2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport

More information

Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease

Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease Cigna Specialty Pharmacy Services Limited Distribution and Risk Evaluation Mitigation (RE) Drug List Last updated on 04/06/2015 Medication Brand Name Condition Actemra Rheumatroid Arthritis Acthar Seizure

More information

encourages correct prescription drug use for a particular diagnosis, promotes the safe use of prescription drugs, and helps reduce drug costs.

encourages correct prescription drug use for a particular diagnosis, promotes the safe use of prescription drugs, and helps reduce drug costs. Prior Authorization Your health plan participates in a Prior Authorization (PA) program for specific prescription drugs. This means that Caremark must review certain information provided by your doctor

More information

DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION

DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION ACTEMRA (toclizumab) 10/21/13 ADASUVE (loxapine aerosol powder breath activated) 01/24/14 ADDAMEL N INJ (Trace Min (CR-CU-F-FE-I-MN-MO-SE-ZN) INJ) 05/20/13 ADYNOVATE (Antihemophilic Factor Recomb Pegylated

More information

NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only

NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only Updated 5.5.14 NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only 68152-0103-03 A9543 YTTRIUM Y-90 IBRITUMOMAB TIUXETAN ZEVALIN Y-90 VIAL 9/1/2013 12/31/2013 50419-0320-05

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE August 20, 2015 SUBJECT EFFECTIVE DATE September 28, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER 99-15-08 BY Specialty Pharmacy Drug Program Pharmacy Services Leesa M. Allen, Deputy Secretary Office

More information

Meridian Health Plan Drugs Covered under the Medical Benefit* Updated 09/2015 PA Required

Meridian Health Plan Drugs Covered under the Medical Benefit* Updated 09/2015 PA Required J0129 J0130 J0586 J9264 J3262 J0800 J0135 C9287 J0178 J0180 J9015 J1931 J0215 J9010 J0205 J0220 J9305 J2469 J0256 J0207 J7308 J0285 J0288 J0287 J0289 Abatacept Injection Abciximab AbobotulinumtoxinA Abraxane

More information

MEDICAL BENEFIT BOOKLET

MEDICAL BENEFIT BOOKLET MEDICAL BENEFIT BOOKLET For Administered By Si usted necesita ayuda en español para entender este documento, puede solicitarla gratuitamente llamando a Servicios al Cliente al número que se encuentra en

More information

Filtration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010

Filtration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010 iltration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010 SUMMARY O CHANGES: Green = Added from literature (Lexi-Comp, Micromedex, pkg inserts) Yellow =

More information

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

Effective: July 28, 2015. Arizona Prior Authorization Requirements Health Net Access, Inc.

Effective: July 28, 2015. Arizona Prior Authorization Requirements Health Net Access, Inc. Effective: July 28, 2015 Arizona Prior Authorization Requirements Health Net Access, Inc. The following services, procedures and equipment are subject to prior authorization requirements (unless noted

More information

Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List

Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List 05.03.382.1

More information

Commonwealth of Massachusetts Executive Office of Health and Human Services Office of Medicaid www.mass.gov/masshealth

Commonwealth of Massachusetts Executive Office of Health and Human Services Office of Medicaid www.mass.gov/masshealth Executive Office of Health and Human Services Office of Medicaid www.mass.gov/masshealth February 2012 TO: FROM: RE: Physicians Participating in Julian J. Harris, M.D., Medicaid Director (2012 HCPCS) This

More information

Participating Provider Precertification List

Participating Provider Precertification List Participating Provider Precertification List Effective August 1, 2016 Reference all general precertification information. Applies to all Coventry commercial and Medicare benefit plans that include a precertification

More information

ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers. May 1, 2012

ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers. May 1, 2012 ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers May 1, 2012 Agenda Topics for Today 1. Program Summary Specialty Injectable Drugs in scope EmblemHealth

More information

INPATIENT SERVICES Commercial Medicare. Notification required only, as soon as possible, but no later than 24 hours

INPATIENT SERVICES Commercial Medicare. Notification required only, as soon as possible, but no later than 24 hours Effective: January 1, 2016 Arizona Prior Authorization Requirements HMO (including CommunityCare HMO) Point-of-Service (POS) PPO Advantage (MA) HMO The following services, procedures or equipment are subject

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for

More information

Items Covered Benefit for Preferred Vendor Contact Information. Medicaid ONLY Integra Phone 718-369-0012

Items Covered Benefit for Preferred Vendor Contact Information. Medicaid ONLY Integra Phone 718-369-0012 Department Of Pharmacy (Medicaid, Child Health Plus, Medicare Part B, Qualified Health Plan) Medications Requiring Authorization under Medical Benefit - Fax request to (718) 536-3383 (Last Revised 8/4/15)

More information

PATIENT ASSISTANCE PROGRAMS

PATIENT ASSISTANCE PROGRAMS PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed

More information

602 Nonpayable CPT Codes

602 Nonpayable CPT Codes 6-1 601 Introduction providers must refer to the American Medical Association s Current Procedural Terminology (CPT) 2015 code book for the descriptions for the service codes when billing for services

More information

Brand Generic J-Code Covered Uses Required Medical Information and Criteria

Brand Generic J-Code Covered Uses Required Medical Information and Criteria FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J-Code Prior Authorizations & Required Clinical Information Medicaid, Family Health Plus, Child Health Plus, NY State of Health Brand Generic J-Code

More information

Special Authorization

Special Authorization Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization?

More information

Pre-authorization Form

Pre-authorization Form Kalispell Public Schools 2014 Please verify services not listed below on the pre-authorization list with Benefits and Eligibility (Customer Service) to determine coverage. Preauthorization lists do not

More information

Cost Differences in Cancer Care Across Settings

Cost Differences in Cancer Care Across Settings Cost Differences in Cancer Care Across Settings August 2013 THE MORAN COMPANY 1 Cost Differences in Cancer Care Across Settings In a prior memorandum, we presented evidence documenting the growing share

More information

Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION

Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Contents Page Program Overview 1 Process for Obtaining Authorization 2 Contacts 2

More information

Rheumatic Diseases, Psoriasis, and Crohn s Disease

Rheumatic Diseases, Psoriasis, and Crohn s Disease Rheumatic Diseases, Psoriasis, and Crohn s Disease What does this handout cover? This handout has information about rheumatic disease, psoriasis, and Crohn s disease. It also has information on how these

More information

Medi-Cal Expansion, Mental Health Services and Changes to Medi-Cal Prior Authorization Requirements

Medi-Cal Expansion, Mental Health Services and Changes to Medi-Cal Prior Authorization Requirements REGULATORY DECEMBER 19, 2013 UPDATE 13-545 12 PAGES Medi-Cal Expansion, Mental Health Services and Changes to Medi-Cal Beginning January 1, 2014, Medi-Cal coverage is expanding under the Affordable Care

More information

22 Medicare Provider Manual

22 Medicare Provider Manual 22 Medicare Provider Manual Table of Contents Title Page Introduction 2 Important Contact Information 4 Member Eligibility & Plan Design 5 ID card sample 8 Provider Reconsideration Process 9 Member Grievance

More information

United Healthcare Medicare Solutions

United Healthcare Medicare Solutions United Healthcare Medicare Solutions Part B Specialty Drug Prior Authorization Program Provider Training Agenda Program Mission Program Description Implementation Timeline Program Resources Prior Authorization

More information

CONNECTICARE, INC. & AFFILIATES

CONNECTICARE, INC. & AFFILIATES CONNECTICARE, INC. & AFFILIATES INSERT PAGE FOR PRE-CERTIFICATION AND PRE- AUTHORIZATION LISTS UPDATE Applies to all ConnectiCare health plans, except the ConnectiCare Network USA-PPO Plan and as otherwise

More information

MEDICARE PART B. Expenditures for New Drugs Concentrated among a Few Drugs, and Most Were Costly for Beneficiaries

MEDICARE PART B. Expenditures for New Drugs Concentrated among a Few Drugs, and Most Were Costly for Beneficiaries United States Government Accountability Office Report to the Ranking Member, Committee on the Budget, House of Representatives October 2015 MEDICARE PART B Expenditures for New Drugs Concentrated among

More information

Specialty Drug Program RX Benefit Member Guide

Specialty Drug Program RX Benefit Member Guide Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete

More information

Cardiac Procedure: Outpatient Office Inpatient Emergent/Urgent Diagnostic Catheterization Required Required Not Not required

Cardiac Procedure: Outpatient Office Inpatient Emergent/Urgent Diagnostic Catheterization Required Required Not Not required Important Changes In Notification and Prior Authorization Procedures (This is revised from the article that was posted in the September 2012 Network Bulletin. Changes are in Section 3, Standardization

More information

Analysis of hospital pharmaceuticals

Analysis of hospital pharmaceuticals Danish Ministry of Health and Prevention Analysis of hospital pharmaceuticals Country report - The Netherlands March 2009 COWI A/S Parallelvej 2 2800 Kongens Lyngby Telefon 45 97 22 11 Telefax 45 97 22

More information

UMASTER PREFERRED DRUG LIST (DRUG FORMULARY) Effective July 1, 2015 RA05/15.654

UMASTER PREFERRED DRUG LIST (DRUG FORMULARY) Effective July 1, 2015 RA05/15.654 UMASTER PREFERRED DRUG LIST (DRUG FORMULARY) Effective July 1, 2015 1PU 2PU 3PU 4PU UPU UPU UPU UPU P P P P P Tier Master List (PDL) (Drug Formulary) Effective July 1, 2015 THE BLUEGRASS FAMILY HEALTH

More information

Antibody Drug Nomenclature: -umab -zumab -ximab -omab. What is INN a Name? WHO Has Been Changing Them?

Antibody Drug Nomenclature: -umab -zumab -ximab -omab. What is INN a Name? WHO Has Been Changing Them? Antibody Drug Nomenclature: What is INN a Name? WHO Has Been Changing Them? Paul J. Carter Staff Scientist and Senior Director Antibody Engineering Genentech Inc. -umab -zumab -ximab -omab Antibody Engineering

More information

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments

More information

February 2016 Medicaid Bulletin

February 2016 Medicaid Bulletin February 2016 Medicaid Bulletin In this Issue.... Page All Providers NCTracks Updates.......2 NCTracks Updates Durable Medical Equipment... 6 Clinical Coverage Policy 1S-4, Genetic Testing... 7 Clinical

More information

2014 Apple Health Benefit Grid

2014 Apple Health Benefit Grid 2014 Apple Health Benefit Grid BH+/BH S-Med/S-Chip Requirements Adult Services: Age 19 Children Services: Age 18 Abortion, Spontaneous (miscarriage) Alcohol and Substance Abuse Services, Inpatient, Outpatient,

More information

Non-urgent Pre-service requests---within 3 business days of receipt of request. Urgent Pre-service requests---within 72 hours of receipt of request

Non-urgent Pre-service requests---within 3 business days of receipt of request. Urgent Pre-service requests---within 72 hours of receipt of request Health Republic Insurance of New York Services Requiring Preauthorization Effective January 1, 2015 Applies to all Lines of Business unless specifically noted Non-Participating Provider services are not

More information

COVERAGE MANAGEMENT PROGRAMS

COVERAGE MANAGEMENT PROGRAMS COVERAGE MANAGEMENT PROGRAMS The purpose of coverage management programs is to help improve the quality of care by encouraging the right patient and provider behaviors to avoid compromised care and unnecessary

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

January 1, 2016 At A Glance. CSEA Civil Service Employees Association

January 1, 2016 At A Glance. CSEA Civil Service Employees Association January 1, 2016 At A Glance CSEA Civil Service Employees Association For Employees of the State of New York represented by Civil Service Employees Association (CSEA) and for their enrolled Dependents;

More information

Great-West s Drug Prior Authorization

Great-West s Drug Prior Authorization Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage

More information

Adalimumab (Humira) Refrigerate at 36º to 46ºF (2º to 8ºC). Contact manufacturer.*** Abbott Laboratories 800-633-9110

Adalimumab (Humira) Refrigerate at 36º to 46ºF (2º to 8ºC). Contact manufacturer.*** Abbott Laboratories 800-633-9110 Detail-Document #241001 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2008 ~ Volume 24 ~ Number 241001 Stability of Refrigerated and

More information

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline

More information

J_Code To NDC Billing Cross Reference Guide

J_Code To NDC Billing Cross Reference Guide J_Code To Billing Cross Reference Guide J0129 Injection, abatacept, 10 mg GENERIC J0129 UN 250 MG 250 MG 25 ABATACEPT/MALTOSE J0150 6 MG Injection adenosine 6 MG GENERIC J0150 ML 3 MG/ML 3 MG ML 1 0.5

More information

ClearScript Prior Authorization Drug List

ClearScript Prior Authorization Drug List ClearScript Prior Authorization Drug List Prior authorization is a cost-savings program intended to ensure that medications are utilized in a manner that is consistent with your pharmacy benefit. For the

More information

State of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing

State of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing Bobby Jindal GOVERNOR State of Louisiana Department of Health and Hospitals Bureau of Health Services Financing Kathy H. Kliebert SECRETARY The purpose of this memo is to advise you that effective September

More information

Monoclonal antibody (mab) products are currently a fast

Monoclonal antibody (mab) products are currently a fast Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,

More information

Coverage and Pricing. of Drugs That Can Be Covered Under. Part B and Part D

Coverage and Pricing. of Drugs That Can Be Covered Under. Part B and Part D Coverage and Pricing Elizabeth Hargrave NORC at the University of Chicago Jack Hoadley of Drugs That Can Be Covered Under Part B and Part D Jennifer Thompson Georgetown University MedPAC A study conducted

More information

To start using DocFind today, go to www.aetna.com/docfind/custom/uva. Registration is not required.

To start using DocFind today, go to www.aetna.com/docfind/custom/uva. Registration is not required. Dear University of Virginia Faculty and Staff: Welcome to Aetna! One of the nation's leading health benefits companies, Aetna provides members with information and resources to help you make smart decisions

More information

Michał Pilkiewicz Country Manager IMS Health Poland

Michał Pilkiewicz Country Manager IMS Health Poland The Pharmaceutical Market in Poland - government regulation, pricing and reimbursement of medicines, in particular What is the influence on the market situation? Michał Pilkiewicz Country Manager IMS Health

More information

An Economic Assessment of ANCO Member Practices Roberta Buell, M.B.A. OnPoint Oncology LLC. Patricia Falconer, M.B.A.

An Economic Assessment of ANCO Member Practices Roberta Buell, M.B.A. OnPoint Oncology LLC. Patricia Falconer, M.B.A. An Economic Assessment of ANCO Member Practices Roberta Buell, M.B.A. OnPoint Oncology LLC Patricia Falconer, M.B.A. Health Options José Luis González Association of Northern California Oncologists Abstract

More information

PHAR 6766: Biotechnology-Derived Drugs

PHAR 6766: Biotechnology-Derived Drugs PHAR 6766: Biotechnology-Derived Drugs Course Syllabus Fall 1.0 Credits This course adheres to the College of Pharmacy Central Syllabus. Please see the following link for this information: https://docs.google.com/a/umn.edu/document/d/1artq5e1rbzxe8letwo7be8k8snzaegmmz_qcw8yj-ii/edit?pli=1

More information

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG Monitoring Usage in Wales of s Appraised by NICE and AWMSG October 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology

More information

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines Clinical Utilization Management Guidelines The Clinical Utilization Management (UM) Guidelines on this list represent the Clinical UM Guidelines adopted by the Medical Operations Committee for the Government

More information

Multiple Sclerosis Center of Nebraska

Multiple Sclerosis Center of Nebraska Multiple Sclerosis Center of Nebraska Date: Initial Visit Patient Information (Multiple Sclerosis) To be Completed Before Appointment Patient Name: DOB: Address: Social Security Number: Power of Attorney

More information

Specialty drug trend

Specialty drug trend 2 0 0 8 Specialty drug trend r e p o r t Specialty Pharmacy A n E x p r e s s S c r i p t s C o m p a n y Lead Authors Emily Cox, PhD, RPh Yakov Svirnovskiy, MA Chris Peterson, PharmD Aimee Tharaldson,

More information

Cancer Care Quality Program. Treatment Pathways

Cancer Care Quality Program. Treatment Pathways Cancer Care Quality Program Treatment Pathways REVISED: UPDATES EFFECTIVE DECEMBER 1, 2015 1 TABLE OF CONTENTS Contents CANCER CARE QUALITY PROGRAM 3 BLADDER CANCER PATHWAYS 4 BREAST CANCER PATHWAYS 5

More information

Provider Manual. This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc.

Provider Manual. This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc. 2014 Provider Manual This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc. We hope you find this information and the enclosed documents

More information

Health Choice Arizona

Health Choice Arizona Health Choice Arizona PRIOR AUTHORIZATION GUIDELINES Health Choice Arizona presents these guidelines for prior authorized services for members who live in the following counties: Apache, Coconino, Gila,

More information

AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, PASS

AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, PASS Final Belgian list: marketing name Active substance MAH Reason on list ADASUVE LOXAPINE ALEXZA UK LTD New AS ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD New AS, Cond Auth, PASS

More information

Multiple Sclerosis Step Therapy and Quantity Limit Criteria

Multiple Sclerosis Step Therapy and Quantity Limit Criteria Multiple Sclerosis Step Therapy and Quantity Limit Criteria Tysabri (natalizumab) will NOT be included in this step therapy program for Blue Cross and Blue Shield of Illinois because this plan does not

More information

4Precertification. and Referrals. Precertification...59 Referrals (Gated Plans Only)...73

4Precertification. and Referrals. Precertification...59 Referrals (Gated Plans Only)...73 4Precertification and Referrals Precertification.....................59 Referrals (Gated Plans Only)............73 Section 4 Precertification and Referrals 58 www.oxfordhealth.com Precertification and

More information

SPECIAL AUTHORIZATION GUIDELINES

SPECIAL AUTHORIZATION GUIDELINES 91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage

More information

Medical Policies and Clinical Utilization Management Guidelines

Medical Policies and Clinical Utilization Management Guidelines providers.amerigroup.com Medical Policies and Clinical Utilization Management Guidelines Amerigroup Iowa, Inc. uses nationally recognized, evidence-based Medical Policies and Clinical Utilization Management

More information

Towards a New Model of Delivery of Care

Towards a New Model of Delivery of Care Towards a New Model of Delivery of Care What can we do Different to Provide Better Delivery of Care? Algis Jovaisas, MD,FRCPC Division of Rheumatology University of Ottawa Current Modelsurrent Private

More information

That quote is never more accurate

That quote is never more accurate compliance Oncology Reimbursement Update 2015 BY CINDY PARMAN, CPC, CPC-H, RCC Change is inevitable except from a vending machine. robert c. gallagher, businessman and former director of the green bay

More information

Local Coverage Determination (LCD): Chemotherapy Drugs and their Adjuncts (L28576)

Local Coverage Determination (LCD): Chemotherapy Drugs and their Adjuncts (L28576) Local Coverage Determination (LCD): Chemotherapy Drugs and their Adjuncts (L28576) Contractor Information Contractor Name Wisconsin Physicians Service Insurance Corporation LCD Information Document Information

More information

Special Resource. Drugs to be Used with a Filter for Preparation and/or Administration

Special Resource. Drugs to be Used with a Filter for Preparation and/or Administration Hospital Pharmacy Volume 42, Number 4, pp 378 382 2007 Wolters Kluwer Health, Inc. Special Resource Drugs to be Used with a Filter for Preparation and/or Administration Prepared by: Wolters Kluwer Health/Facts

More information

Pharmacotherapy of Autoimmune Disorders

Pharmacotherapy of Autoimmune Disorders PHARMACY / MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Pharmacotherapy of Autoimmune Disorders Number 5.01.550

More information

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 March 2015 Welcome to the first COMPARE report. This report provides information

More information

Prescription Drug Benefit Description

Prescription Drug Benefit Description Prescription Drug Benefit Description Herein called Description Prescription Drug Program For State of Kansas Employees Health Plan This booklet describes the Prescription Drug benefits available through

More information

How Coding Impacts the Revenue Cycle

How Coding Impacts the Revenue Cycle How Coding Impacts the Revenue Cycle Topics to be Covered: How Coding Impacts the Revenue Cycle National Correct Coding Initiative Medically-Unlikely Edits AWV & IPPE with Separate E/M Visits Non-Specific

More information

PATIENT APPLICATION FORM INSTRUCTIONS

PATIENT APPLICATION FORM INSTRUCTIONS INSTRUCTIONS The Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. To apply online, access program information

More information

CAUTION: Read the ICD-9 Policy Holding Library page about policy in this document.

CAUTION: Read the ICD-9 Policy Holding Library page about policy in this document. Injections: Drugs E-H Policy 1 This section outlines policy related to billing for injection services, listed in alphabetical order by generic drug name or drug type. For general billing policy information

More information

2016 Medicaid Preapproval Criteria

2016 Medicaid Preapproval Criteria 2016 Medicaid Preapproval Criteria ABILIFY MAINTENA... 11 ACTIMMUNE... 12 ADAGEN... 13 ADCETRIS... 14 ADCIRCA... 15 ADEMPAS... 16 AFINITOR... 18 ALDURAZYME... 19 ALFERON-N... 20 ALGLUCOSIDASE ALFA... 21

More information

Safety Policy Manual Policy No. 106

Safety Policy Manual Policy No. 106 Safety Policy Manual Policy No. 106 Policy: Hazardous Drugs (Including Chemotherapeutic) Page 1 of 11 APPLICATION NYU Langone Medical Center (NYULMC) PURPOSE To protect employees from exposure to hazardous

More information

A guide for reluctant pharmacists

A guide for reluctant pharmacists PHARMACY REIMBURSEMENT A guide for reluctant pharmacists Anne T. Jarrett, MS, RPh Anne T. Jarrett, MS, RPh Assistant Director of Pharmacy Wake Forest University Baptist Hospital Winston-Salem, North Carolina

More information

Student Employee Health Plan (SEHP) for Graduate Student Employees

Student Employee Health Plan (SEHP) for Graduate Student Employees New York State Health Insurance Program Student Employee Health Plan (SEHP) for Graduate Student Employees January 1, 2009 For Graduate Student Employees and for their enrolled Dependents and for COBRA

More information

Kaiser Permanente s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use

Kaiser Permanente s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use Perspective Kaiser Permanente s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use A large integrated delivery system reports on its management of specialty pharmaceuticals.

More information

Approaches to Development of Long Acting Injection Formulations Challenges and Solutions

Approaches to Development of Long Acting Injection Formulations Challenges and Solutions Approaches to Development of Long Acting Injection Formulations Challenges and Solutions Roger G. Harrison PhD Injectable Products, Management Forum, The Institute of Directors, London, 24-25 October 2005

More information

Medical Policies and Clinical Utilization Management Guidelines

Medical Policies and Clinical Utilization Management Guidelines providers.amerigroup.com Medical Policies and Clinical Utilization Management Guidelines Amerigroup* began using Anthem s nationally recognized, evidence-based Medical Policies and Clinical Utilization

More information

Administrative Code. Title 23: Medicaid Part 224 Immunizations

Administrative Code. Title 23: Medicaid Part 224 Immunizations Administrative Code Title 23: Medicaid Part 224 Immunizations Table of Contents Title 23: Division of Medicaid... 1 Part 224: Immunizations... 1 Part 224 Chapter 1: General... 1 Rule 1.1: Reserved... 1

More information

Classification of Hazardous Drugs by NIOSH

Classification of Hazardous Drugs by NIOSH Classification of Hazardous Drugs by NIOSH Thomas H. Connor, PhD Research Biologist National Institute for Occupational Safety and Health NIOSH Goals Protect workers from exposure to hazardous drugs Provide

More information

HCPCS J Codes Last Updated January 2014

HCPCS J Codes Last Updated January 2014 J s Last Updated January 2014 Term J0120 INJECTION, TETRACYCLINE, UP TO 250 MG D 19860101 19970101 J0128 INJECTION, ABARELIX, 10 MG C 20050101 20050101 J0130 INJECTION ABCIXIMAB, 10 MG D 19990101 19990101

More information

New Oncology Drug Approvals and FDA Review in the United States

New Oncology Drug Approvals and FDA Review in the United States By Samantha A. Roberts, Jeff D. Allen, and Ellen V. Sigal Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe doi: 10.1377/hlthaff.2011.0231

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #337: Tuberculosis Prevention for Psoriasis,Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier National Quality Strategy Domain: Effective Clincal Care

More information

Drugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera

Drugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera Abstral Acthar Hp Adcirca Adempas Affinitor Amitiza Amitriptyline Ampyra Androgel Androderm Androxy Aranesp Arcalyst Aubagio Avonex Bosulif Bydureon Byetta Cimzia Cinryze Clomipramine Cometriq Copaxone

More information

Specialty Pharmacy Program Drug List

Specialty Pharmacy Program Drug List Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in-network benefits/coverage for these drugs, these

More information

Medications most likely to be seen in primary care

Medications most likely to be seen in primary care Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

IMMUNOMODULATORS. IMMU 7630 Fall 2015

IMMUNOMODULATORS. IMMU 7630 Fall 2015 IMMUNOMODULATORS IMMUNODODULATION. By immunomodulation we mean the use of drugs, alone or in combination with other maneuvers, to change the function of all, or part, of the immune system. In general,

More information